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Abstract Magnolol, honokiol, and obovatol are well-
known bioactive constituents of the bark of Magnolia ofﬁ-
cinalis and have been used as traditional Chinese medicines
for the treatment of neurosis, anxiety, and stroke. We
recently isolated novel active compound (named 4-O-
methylhonokiol) from the ethanol extract of Magnolia ofﬁ-
cinalis.Thepresentstudyaimedtotesttwodifferentdosesof
ethanol extracts of Magnolia ofﬁcinalis (5 and 10 mg/kg/
mouse, p.o., 1 week) and 4-O-methylhonokiol (0.75 and
1.5 mg/kg/mouse, p.o., 1 week) administered for 7 days on
memory impairment induced by scopolamine (1 mg/kg
body weight i.p.) in mice. Memory and learning were eval-
uated using the Morris water maze and the step-down
avoidance test. Both the ethanol extract of Magnolia
ofﬁcinalis and 4-O-methylhonokiol prevented memory
impairment induced by scopolamine in a dose-dependent
manner. The ethanol extract of Magnolia ofﬁcinalis and
4-O-methylhonokiol also dose-dependently attenuated
the scopolamine-induced increase of acetylcholinesterase
(AChE) activity in the cortex and hippocampus of mice, and
inhibited AChE activity in vitro with IC50 (12 nM). This
study, therefore, suggests that the ethanol extract of
Magnolia ofﬁcinalis and its major ingredient, 4-O-methyl-
honokiol, may be useful for the prevention of the
development or progression of AD.
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Introduction
Alzheimer’s disease (AD), a type of progressive dementia,
is a neurodegenerative disorder characterized by a pro-
gressive cognitive decline resulting from selective neuronal
dysfunction, synaptic loss, and neuronal cell death [1–5].
Numerous medications are undergoing testing for the
treatment of the dementia associated with AD, however,
there is no known cure for AD. Studies of patients with AD
revealed the depleted levels of acetylcholine in an AD
patient’s brain. Centrally acting cholinergic drugs have
been reported to increase the regional cerebral blood ﬂow of
acetylcholine in the brain regions affected by AD [6]. Thus,
the maintaining of the acetylcholine level in the brain is
important for the cure of AD patients. One method for this
is blocking the activity of acetylcholinesterase (AChE),
the enzyme-degrading acetylcholine. The cholinesterase
inhibitors (AChEI) donepezil hydrochloride, galantamine
hydrobromide, and rivastigmine tartrate are the current
approved drugs for the treatment of AD patients [7].
However, AChEI presents some limitations, such as their
short half-lives and excessive side effects caused by the
activation of peripheral cholinergic systems, as well as
hepatotoxicity, which is the most frequent and important
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DOI 10.1007/s11418-009-0330-zside effect of these drug therapies [8–11]. For this reason,
alternative and complementary therapies need to be devel-
oped. Thus, novel AChE inhibitors from plant sources could
be valuable alternatives in the context of the treatment of
AD. Several studies have shown the neuroprotective and/or
cognition-enhancing properties of natural products and their
components using different animal models [12–18].
Magnolol, honokiol, and obovatol are well-known bio-
active constituents of the bark of Magnolia ofﬁcinalis.
Magnolol and honokiol have been known to have various
pharmacological activities, such as anti-inﬂammatory, anti-
bacterial, and anti-allergic activities, and have also been
used as traditional Chinese medicines for the treatment of
neurosis, anxiety, stroke, fever, and headache [19]. Hon-
okiol was known to promote a potassium-induced release
of acetylcholine in a rat hippocampal slice [20] and to
enhance neurite sprouting [21]. In addition, magnolol and
honokiol exhibited an AChE inhibitory property in rat
spleen microsomes and human polymorphonuclear leuko-
cytes [22]. Moreover, we recently found that obovatol has
high anti-anxiety activity [23] and anti-AChE activity
(unpublished data). Among various constituents of the
ethanol extract of Magnolia ofﬁcinalis, we have isolated a
major compound (40–50%) identiﬁed as 4-O-methylhon-
okiol that has not demonstrated any pharmacological
activities. Therefore, in this study, we investigated whether
the ethanol extract of Magnolia ofﬁcinalis and 4-O-meth-
ylhonokiol could inhibit the memory impairment induced
by scopolamine through the inhibition of AChE.
Materials and methods
Animals
Male ICR mice weighing 25–30 g (Samtako, Gyeonggi-do,
Korea) were maintained in accordance with the guidelines
of the National Institute of Toxicological Research of the
Korea Food and Drug Administration for the care and use
of laboratory animals. Animals were housed three per cage,
allowed access to water and food ad libitum, and main-
tained on a 12-h light/dark cycle regulated at 23C room
temperature. The experiments were performed at least
1 week after their arrival in individual home cages. Sixty
mice were used for the water maze test and another 60
mice were used for the step-through test. Ten mice per
group were used for each of the memory tests; Group 1:
control, Group 2: scopolamine-treated, Group 3: scopol-
amine with 5 mg/kg ethanol extract, Group 4: scopolamine
with 10 mg/kg ethanol extract, Group 5: scopolamine with
0.75 mg/kg 4-O-methylhonokiol, Group 6: scopolamine
with 1.5 mg/kg 4-O-methylhonokiol. The mice used for the
water maze test were used for the assay of AChE activity.
Materials
The bark of Magnolia ofﬁcinalis Rehd. et Wils. was dried in
the shade at room temperature and stored in a dark, cold
room until use. The air-dried bark of Magnolia ofﬁcinalis
Rehd. et Wils. (3 kg) was cut into pieces and extracted
twice with 95% (v/v) ethanol (four times as much as the
weight of the dried plants) for 3 days at room temperature.
After ﬁltration through the 400-mesh ﬁlter cloth, the ﬁltrate
was ﬁltered again through ﬁlter paper (Whatman Grade No.
5) and concentrated under reduced pressure. The combined
extract (450 g) was suspended in H2O and the aqueous
suspension was extracted with n-hexane, ethyl acetate, and
n-BuOH, respectively. The n-hexane layer was evaporated
to dryness to give a residue (70 g), which was chromato-
graphed on silica gel with n-hexane:ethyl acetate (9:1)
gradient to yield a crude fraction that included 4-O-meth-
ylhonokiol. This fraction was repeatedly puriﬁed by silica
gel chromatography using n-hexane:ethyl acetate as the
eluent to obtain pure 4-O-methylhonokiol (Fig. 1a). 4-O-
methylhonokiol was identiﬁed by
1H-NMR and
13C-NMR.
The results of the NMR data are as follows and are in
agreement with previously published data [24].
1H-NMR
(400 MHz, CDCl3): d 3.36 (2H, d, J = 7 Hz, H-7), 3.44
(2H, d, J = 7 Hz, 70-H), 3.89 (3H, s, OMe), 5.05–5.14 (5H,
m, H-9, H-90, OH), 5.93–6.07 (2H, m, H-8, H-80), 6.92 (1H,
d, J = 7 Hz, Ar-H), 6.97 (1H, d, J = 8 Hz, Ar-H), 7.04–
7.08 (2H, m, Ar-H), 7.24–7.31 (2H, m, Ar-H).
13C-NMR
(100 MHz, CDCl3): d 34.5 (C-7), 39.6 (C-70), 55.8 (OMe),
111.2 (C-30), 115.7 (C-40), 115.8 (C-9), 116.1 (C-90), 128.0
(C-10), 128.1 (C-6), 129.0 (C-3), 129.2 (C-1), 130.0 (C-5),
130.4 (C-60), 130.7 (C-2), 132.4 (C-50), 136.7 (C-8), 138.0
(C-80), 151.0 (C-20), 157.2 (C-4). The ethanol extract of
Magnolia ofﬁcinalis contained 16.6% 4-O-methylhonokiol,
followed by 16.5% honokiol and 12.9% magnolol, and
42–45% others.
Passive avoidance performance test
The passive avoidance performance test is widely accep-
ted as a simple and rapid method for memory testing [24].
The passive avoidance response was determined using a
‘step-through’ apparatus (Med Associates Inc., Vermont,
USA) that consisted of an illuminated and a dark com-
partment (each of dimensions 20.3 9 15.9 9 21.3 cm)
adjoining each other through a small gate with a grid
ﬂoor, 3.175-mm stainless steel rod set 8 mm apart. On a
training trial, the ICR mice were placed in the illuminated
compartment facing away from the dark compartment.
When the mice moved completely into the dark com-
partment, it received an electric shock (1 mA, 3 s
duration). Then, the mice were returned to their home
cage. Twenty-four hours later after the training trial, the
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123mice were placed in the illuminated compartment and the
latency period to enter the dark compartment deﬁned as
‘retention.’ The time when the mice entered the dark
compartment was recorded and described as step-through
latency. Scopolamine (1 mg/kg) was injected intraperito-
neally (i.p.) into mice 30 min before the retention trial.
The retention trials were set at a limit of 180 s of cut-off
time.
Water maze test
The water maze test is a widely accepted method for
memory testing, and we performed this test following the
method described by Morris et al. [25]. Maze testing was
performed by the SMART-CS (Panlab, Barcelona, Spain)
program and equipment. A circular plastic pool (height
35 cm, diameter 100 cm) was ﬁlled with milky water and
kept at 22–25C. An escape platform (height 14.5 cm,
diameter 4.5 cm) was submerged 0.5–1 cm below the
surface of the water in position. On training trials, the mice
were placed in a pool of water and allowed to remain on
the platform for 10 s, and then returned to the home cage.
The mice that did not ﬁnd the platform within 60 s were
placed on the platform for 10 s. Twenty-four hours after
the last training trial (six training trials, 2 times/day for
3 days), the mice were given the test trial. Scopolamine
(1 mg/kg, i.p.) was injected into mice 30 min before the
test trial. They were allowed to swim until they discovered
the escape platform. The escape latency, escape distance,
swimming speed, and swimming pattern of each mouse
was monitored by a camera above the center of the pool
connected to the SMART-LD program (Panlab, Barcelona,
Spain).
AChE activity assay
After behavior testing, the animals were perfused with PBS
under inhaled chloroform anesthetization. The brains were
immediately collected in the same manner and frozen
stored at -20C, and separated into cortical and hippo-
campal regions. Brain tissues were homogenized with PBS
and lyzed by 60 min of incubation on ice. The lysate was
centrifuged at 15,000 rpm for 15 min and the supernatant
was used for the assays. AChE activity was determined by
Ellman’s method [26]. Brieﬂy, 5 ll of sample was mixed
with 200 ll of reaction buffer (0.5 mM PBS pH 7.4)
containing 0.02% DTNB (5,50-dithio-bis-2-nitrobenzoic
acid), 0.02% acetylcholine, and 0.1 mM isoOMPA (tetra-
isopropyl pyrophosphoramide). The activity of the enzyme
was determined after 5 min of incubation at 37C and
stopped with 1 mM BW284c51, a potent selective inhibitor
of AChE. The reaction mixture was converted to yellow
color. The optical density was measured at 405 nm and
then expressed as units of the quantity (lM) of the ace-
tylcholine that were hydrolyzed to thiocholine per 1 min
per mg. Speciﬁc activity was standardized by the amount
(mg) of protein of the sample (lM/min/mg protein).
To test the in vitro AChE activity, the whole mouse brain
was homogenized in a glass Teﬂon homogenizer containing
ten volumes of homogenization buffer (12.5 mM sodium
phosphate buffer, pH 7.0, 400 mM NaCl) and then centri-
fuged at 1,0009g for 10 min at 4C. The supernatant was
used as an enzyme source for the assay. Aliquots of diluted
4-O-methylhonokiol were then mixed with reaction buffer
and reacted at room temperature for 5 min and the activity
was determined by the same method as described above.
The concentrations of 4-O-methylhonokiol required to
Pretreatment of ethanol extract 
of M. Officinalis (5 or 10 mg/kg, 
p.o.) or 4-O-Methylhonokiol 
(0.75 or 1.5 mg/kg, p.o.)
0 7 8 Training trials 6 times      
(2 times per day for 3 days)
10
Injection of scopolamine
(1 mg/kg, i.p.)
13 Testing trials  for 4 days
after scopolamine treatment
Day
A
B
Fig. 1 Chemical structure
of 4-O-methylhonokiol (a) and
experimental scheme (b)
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123inhibit AChE activity by 50% (IC50) were calculated using
enzymeinhibitiondoseresponsecurves.Tacrinewasusedas
a positive control.
Statistics
The data were analyzed using GraphPad Prism 4 software
(Version 4.03, GraphPad Software, Inc.). The data are
presented as mean ± standard error (SE). The homogene-
ity of variances was assessed using a Bartlett test. If
variances were homogeneous, differences between groups
and treatment were assessed by one-way or two-way
analysis of variance (ANOVA). If the P-value in the
ANOVA test was signiﬁcant, the differences between pairs
of means were assessed by Dunnet’s test. One-way
ANOVA was used to analyze data for AChE, while data
obtained from the water Morris maze (swimming distance,
escape latency, and average speed) were analyzed using
two-way ANOVA. When variances were not homoge-
neous, the Kruskal–Wallis test was used to assess
differences between groups for nonparametric analyses.
Data from the step-through avoidance test (latency) were
analyzed using the nonparametric tests mentioned above,
followed by Dunnet’s test. A value of P\0.05 was con-
sidered to be statistically signiﬁcant.
Results
Effect of the ethanol extract of Magnolia ofﬁcinalis
and 4-O-methylhonokiol on the memory impairment
induced by scopolamine
Escape latency (s) of animals treated with scopolamine
(1 mg/kg, i.p.) was decreased (12 ± 5.5 s, P\0.01) in
comparison with the control group (28 ± 7.3 s), indicating
that scopolamine induced memory impairment. On the
other hand, the escape latency of animals pretreated with 5
or 10 mg/kg of ethanol extract of Magnolia ofﬁcinalis for
1 week showed signiﬁcant preventive effect on memory
impairment compared to that of scopolamine-treated ani-
mals (24 ± 7.1 s, P[0.05 or 19 ± 6.1 s, P\0.05)
(Fig. 2a). Tacrine (3 mg/kg) also showed a signiﬁcant
preventive effect against scopolamine-induced memory
impairment (25 ± 1.9 s, P[0.05). The escape latency of
animals administered with 0.75 or 1.5 mg/kg 4-O-methyl-
honokiol was approximately 2–3 times longer than that
of scopolamine-treated animals, and showed signiﬁcant
preventive effect on memory impairment (28 ± 1.8 s,
P\0.01 or 33 ± 8.7 s, P\0.01) (Fig. 2b).
To further examine the memory-enhancing activity of
the ethanol extract of Magnolia ofﬁcinalis and 4-O-meth-
ylhonokiol, we determined the improvement of the spatial
memory function of these compounds using the Morris
water maze. The mice were pretreated continuously with
the ethanol extract of Magnolia ofﬁcinalis (5 or 10 mg/kg
into drinking water) and 4-O-methylhonokiol (0.75 or
1.5 mg/kg into drinking water) for 1 week, and then the
animals were given the training trial. After ﬁnishing the
training trial for 3 days (2 times/day, six times training),
scopolamine (1 mg/kg, i.p.) was then injected into the mice
to induce memory impairment. Two-way ANOVA
revealed an effect of the number of days (F3, 144 = 6.981,
P = 0.0002) and the treated groups (F3, 144 = 6.956,
P = 0.0002) on the escape latency, and an effect of the
number of days (F3, 144 = 6.254, P\0.0001) and the
treated groups (F3, 144 = 9.423, P = 0.0005) on the escape
distance.
The escape latency on the next day of training to the
platform was about 450 ± 127 cm and 19 ± 3 s. Scopol-
amine-treated mice arrived slower at the location of the
platform compared to the controls (885 ± 47 cm,
P\0.05; 42 ± 2s , P\0.05). The escape latency of
animals pretreated with 5 or 10 mg/kg ethanol extract of
Magnolia ofﬁcinalis for 1 week showed a memory-
enhancing effect. The escape latency of animals pretreated
with 5 or 10 mg/kg ethanol extract of Magnolia ofﬁcinalis
for 1 week and subsequently treated with scopolamine was
shown to be approximately 2.5 or 2.4 times shorter
(354 ± 40 cm, P\0.05; 16 ± 3s , P\0.05 or
361 ± 50 cm, P\0.05; 17 ± 2s ,P\0.05) than that of
scopolamine-treated animals determined at 4 day after the
training trial (Fig. 3a).
There was also shown to be a signiﬁcant memory-
improving effect by the treatment with 4-O-methylhonok-
iol. Elevated escape latency and escape distance by
scopolamine was inhibited by the time (third and fourth
day) and treatment (1.5 mg/kg). An amount of 1.5 mg/kg
of 4-O-methylhonokiol signiﬁcantly reduced the escape
latency (s) (F3, 39 = 5.983, P\0.05 and P\0.01 at the
third and fourth days after training, respectively) and dis-
tance (cm) (F3, 39 = 4.93, P\0.05 and P\0.01 at the
third and fourth days after training, respectively) (Fig. 3b).
The average speed was not affected by any of the treat-
ments during all days of the evaluation (data not shown).
Effect of the ethanol extract of Magnolia ofﬁcinalis
and 4-O-methylhonokiol on the activities
of AChE induced by scopolamine
In animals treated with scopolamine (1 mg/kg, i.p.), the
AChE activity was signiﬁcantly increased in comparison
with the control group, and in animals pretreated with the
ethanol extract of Magnolia ofﬁcinalis (5 or 10 mg/kg) for
1 week and subsequently treated with scopolamine (1 mg/
kg, i.p.), the AChE activity was signiﬁcantly (P\0.05)
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123suppressed in both the hippocampus and cortex in a dose-
dependent manner (Fig. 4a). In animals pretreated with 4-
O-methylhonokiol (0.75 or 1.5 mg/kg), the AChE activity
was also signiﬁcantly (P\0.05) suppressed in the hippo-
campus and cortex in a dose-dependent manner (Fig. 4b).
By in vitro testing, 4-O-methylhonokiol also inhibited
AChE activity in a concentration (1 nM–100 lM)-depen-
dent manner, with IC50 values of 12 nM. The IC50 value of
tacrine (positive control) was 135.4 nM.
Discussion
Alzheimer’s disease (AD) is a progressive and eventually
fatal disease of the brain, and it is the cause of more than
50% of dementia patients developing in the population
older than 60 years of age [27–30]. A deﬁciency in ace-
tylcholine is probably the single most common cause of
declining memory [20]. AChE modulates acetylcholine to
proper levels by degradation, thus, excessive AChE activ-
ity leads to constant acetylcholine deﬁciency, causing
memory and cognitive impairments in AD [16]. Currently,
AChE inhibitors (AChEI) are the ﬁrst group of drugs for
AD treatment. Several AChEI have been approved by the
FDA for the treatment of AD, such as tacrine (Cognex
),
donepezil (Aricept
), rivastigmine (Exelon
), and galan-
tamine (Reminyl
)[ 10]. However, these drugs have
limitations in their usage, such as their short half-lives and
excessive side effects caused by the activation of peripheral
cholinergic systems, as well as hepatotoxicity [8, 9, 11].
Thus, a complementary therapeutic strategy is required.
Neuroprotective and/or cognition-enhancing properties of
natural products and their components using different
animal models have been suggested as alternative therapies
in several studies [12–18].
In this study, the ethanol extract of Magnolia ofﬁcinalis
and its major ingredient, 4-O-methylhonokiol, recovered
the memory impairment induced by scopolamine, and its
effect may be related to the ability of AChE inhibition. The
step-through latency, which was reduced by scopolamine
treatment, was recovered to 60–70% of the vehicle-treated
control group. The Morris water maze learning task was
used to assess hippocampal-dependent spatial learning
ability [25, 31] and long-term memory [25]. Impairment in
the long-term memory was observed in the scopolamine-
treated group. However, the ethanol extract of Magnolia
A
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Fig. 2 Inhibitory effect of the
ethanol extract of Magnolia
ofﬁcinalis (a) and 4-O-
methylhonokiol (b) on memory
impairment induced by
scopolamine in the passive
avoidance test. Mice were
administered the ethanol extract
of Magnolia ofﬁcinalis at 5.0
and 10.0 mg/kg and 4-O-
methylhonokiol at 0.75 and
1.5 mg/kg for 1 week into
drinking water, and then the
training trial was given on the
last day. After 24 h, the passive
avoidance test was performed.
Scopolamine (i.p., 1 mg/kg)
was treated 30 min before the
test trial as a positive control.
Each value is mean ± standard
error (SE) from ten animals.
#P\0.05 showed a signiﬁcant
difference compared with the
controls. *P\0.05 showed a
signiﬁcant difference compared
with the scopolamine-treated
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123ofﬁcinalis and 4-O-methylhonokiol also signiﬁcantly
shortened the escape latencies prolonged by the scopol-
amine treatment. At the probe trial session, the ethanol
extract of Magnolia ofﬁcinalis and 4-O-methylhonokiol
improved the swimming time and distance within the zone
of the platform to the control level. Collectively, these
behavioral studies suggest that the ethanol extract of
Magnolia ofﬁcinalis improves the long-term memory in an
amnestic mouse model induced by scopolamine treatment,
and 4-O-methylhonokiol may be a major active ingredient.
To conﬁrm the mechanism of the action of the ethanol
extract of Magnolia ofﬁcinalis and its major ingredient, 4-
O-methylhonokiol, their inhibitory activity on AChE was
assessed in vivo. It is well known that the memory-
improving effect of the anti-amnestic effect of tacrine and
donepezil is due to the inhibition of AChE in the brain. The
present data showed that the ethanol extract of Magnolia
ofﬁcinalis and 4-O-methylhonokiol inhibited AChE activ-
ity in a dose-dependent manner in both the cortex and
hippocampus. Thus, it is likely that the memory-improving
effect of the ethanol extract of Magnolia ofﬁcinalis and
4-O-methylhonokiol may be, at least in part, mediated by
the AChE inhibition. AChEI, such as tacrine and donepezil,
causes severe hepatic toxicity, nausea, vomiting, etc., so
these drugs must be used carefully. The efﬁcacy of the
ethanol extract of Magnolia ofﬁcinalis and 4-O-methyl-
honokiol is superior compared with conventional drugs
such as tacrine (Table 1). In the present study, we found
that 5 or 10 mg/kg of ethanol extract of Magnolia ofﬁci-
nalis or 0.75 or 1.5 mg/kg of 4-O-methylhonokiol has a
similar inhibitory effect to 3 mg/kg tacrine on scopol-
amine-induced memory impairment as well as the
inhibition of AChE activity in vivo. The inhibitory effect
on the AChE activity may be related to the inhibitory effect
of 4-O-methylhonokiol on the expression of AChE. We
observed that the elevated expression of AChE by sco-
polamine in both the cortex and hippocampus was
decreased by the treatment with 4-O-methylhonokiol (data
not shown). In the in vivo study, however, we did not
observe clear dose-dependent prevention on the memory
impairment. These unexpected data (similar dose effects)
may be caused by the non differential effect of 4-O-
methylhonokiol by these two doses with only two times the
difference, thus, additional increased or decreased doses
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Fig. 3 Inhibitory effect of the ethanol extract of Magnolia ofﬁcinalis
(a) and 4-O-methylhonokiol (b) on memory impairment induced by
scopolamine in the water maze test. Mice were administered the
ethanol extract of Magnolia ofﬁcinalis at 5.0 and 10.0 mg/kg and 4-
O-methylhonokiol at 0.75 and 1.5 mg/kg for 1 week into drinking
water. The mice were then given training trials six times (2 times/
day), and the test was performed 24 h after the last training trial.
Scopolamine (i.p., 1 mg/kg), as a positive control, was treated 10 min
before the ﬁrst test trial, as shown in the Fig. 1b. Each value is the
mean ± SE from ten animals.
#P\0.05 showed a signiﬁcant
difference compared with the controls. *P\0.05 showed a signif-
icant difference compared with the scopolamine-treated controls
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123could be tested in further studies. We are currently
undertaking another investigation using AD transgenic
mice with three different doses with three times the dif-
ference among the dosing, since the present memory
prevention effects were likely to be saturated, and the
effect was similar to the effect of tacrine. In in vitro ace-
tylcholine esterase, 4-O-methylhonokiol (IC50: 12 nM)
showed more than ten times stronger inhibitory effect than
tacrine (IC50: 135.4 nM). Moreover, the ethanol extract of
Magnolia ofﬁcinalis and 4-O-methylhonokiol originate
from a natural plant, and, thus, side effects could be rela-
tively smaller. In fact, 4-week oral treatment (up to
300 mg/kg) of the ethanol extract of Magnolia ofﬁcinalis to
mice and rats did not show any toxicities in the liver,
kidney, intestine, or cardiovascular and central nervous
systems, and the animals did not have any high cholinergic
symptoms (data not shown). Similar effects of other
ingredients isolated from Magnolia ofﬁcinalis, such as
honokiol and magnolol, were reported to increase acetyl-
choline release in freely moving rats, and these effects may
be related to the inhibitory effects on the AChE activity
[20, 32]. Therefore, from the above behavioral and bio-
chemical data, it can be concluded that the ethanol extract
of Magnolia ofﬁcinalis has an ability to improve or ame-
liorate spatial long-term memory impairment, in part, via
enhancement of the cholinergic nervous system, and
4-O-methylhonokiol may be one of major components
of the memory-improving effect of Magnolia ofﬁcinalis.
It is also noteworthy that cognition-enhancing agents
activate cholinergic transmission via an agonistic or
antagonistic effect on GABAA/benzodiazepine receptor
[33–35], and GABAA/benzodiazepine receptor complex
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Fig. 4 Inhibitory effect of the ethanol extract of Magnolia ofﬁcinalis
(a) and 4-O-methylhonokiol (b) on the AChE activity in the cortex
and hippocampus of scopolamine-induced mice. Mice were treated
with the ethanol extract of Magnolia ofﬁcinalis (5 and 10 mg/kg) and
4-O-methylhonokiol (0.75 and 1.5 mg/kg) for 1 week into drinking
water, and then the AChE activity was measured. Each value is the
mean ± SE from ten animals.
#P\0.05 showed a signiﬁcant
difference compared with the controls. *P\0.05 showed a signif-
icant difference compared with the scopolamine-treated controls
Table 1 Inhibitory activities of acetylcholinesterase (AChE)
Compound Concentration Inhibition (%)
4-O-methylhonokiol 0.1 nM 0.4 ± 0.1
1 nM 10.43 ± 1.43
10 nM 47.4 ± 2.54
100 nM 68.11 ± 7.64
1 lM 78.11 ± 4.34
10 lM 84.15 ± 2.60
Tacrine 1 nM 1.14 ± 1.24
10 nM 9.62 ± 2.32
100 nM 46.54 ± 3.86
1 lM 54.71 ± 7.74
10 lM 61.41 ± 2.94
100 lM 59.97 ± 5.31
Efﬁcacy of inhibition was expressed as percent inhibition versus the
control values (100%). Values represent mean ± SD (n = 5)
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123controls acetylcholine release [36]. We previously found
that obovatol, a similar compound isolated from Magnolia
ofﬁcinalis, has high afﬁnity of GABAA/benzodiazepine
receptor [23]. Therefore, it can also be speculated that the
GABAA/benzodiazepine receptor ligand properties of 4-O-
methylhonokiol may also be related to the ameliorating
effects on scopolamine-induced memory impairment.
Further studies are needed to clarify these points. We are
currently attempting to identify the mechanisms of the
interactions between 4-O-methylhonokiol and GABAA/
benzodiazepine receptors. Taken together, these data sug-
gest that the ethanol extract of Magnolia ofﬁcinalis and 4-
O-methylhonokiol may be useful leading compounds in
anti-AD drug development.
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